Entera Bio vs Inmune Bio
ENTX and INMB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENTX and INMB compare
Entera Bio is the larger company, worth 19 times as much as Inmune Bio ($519M against $26.6M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENTX | INMB |
|---|---|---|
| Size and price | ||
| Market cap | $519M | $26.6M |
| Share price | $3.00 | $0.960 |
| Change, 1 year | 10.7% | −32.4% |
| Change, 5 years | −12.5% | −92.8% |
| Beta (5Y) | −0.34 | 2.98 |
| Employees | 20 | 6 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 71.5× | 1.3× (better) |
| FCF yield | −2.1% | – |
| Growth | ||
| Revenue growth (TTM) | −100% | – |
| Revenue growth, 5Y average | −35.1% | 35.4% (better) |
| EPS growth, 5Y average | −17.9% | – |
| Profitability | ||
| Return on equity | −139% | −74.8% (better) |
| Return on invested capital | −966% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 8.98 (better) | 4.04 |
| Altman Z-score | 14.32 (better) | −10.47 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −0.01% | – |
| Shareholder yield | −0.01% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 6.2% | 15.7% |
| Held by insiders | 11.3% | 16.7% |
| Insider net buying, 12 months | $141K | – |
| Short interest, % of float | 4.6% | 11.5% |
Go deeper
- ENTX stock overview
- ENTX income statement
- ENTX valuation and score
- INMB stock overview
- INMB income statement
- INMB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.